Presse / Média
- 125 - 137 de 137 résultats
Rechercher les résultats
-
Q4/2022: Monthly: Anatara Lifesciences (ANR: 3.40c) in bottom 4% performers of Australian market in past quarter
12/30/22
1 élément de Couverture média
Presse/Média: Research
-
Monthly: Anatara Lifesciences (ANR: 3.80c) rises 27% on high volatility in January 2023
1/31/23
1 élément de Couverture média
Presse/Média: Research
-
Monthly: Anatara Lifesciences (ANR: 3.80c) rises 27% on high volatility in January 2023
1/31/23
1 élément de Couverture média
Presse/Média: Research
-
Weekly: Anatara Lifesciences (ANR: 3.40c) surges 6.2% on weak volume; +0.2c [6.2%]
2/21/23
1 élément de Couverture média
Presse/Média: Research
-
Weekly: Anatara Lifesciences (ANR: 3.0c) shares post worst week in sixteen weeks; -0.4c [11.8%]
2/25/23
1 élément de Couverture média
Presse/Média: Research
-
CHRISTUS St. Michael to break ground March 28 on emergency center
2/25/23
1 élément de Couverture média
Presse/Média: Research
-
Weekly: Anatara Lifesciences (ANR: 3.0c) shares post worst week in sixteen weeks; -0.4c [11.8%]
2/28/23
1 élément de Couverture média
Presse/Média: Research
-
CHRISTUS St. Michael to break ground March 28 on emergency center
3/3/23
1 élément de Couverture média
Presse/Média: Research
-
Researchers at University Health Network Publish New Study Findings on Gene Therapy (Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease)
3/7/23
1 élément de Couverture média
Presse/Média: Research
-
Monthly: Anatara Lifesciences (ANR: 2.80c) trails 94% of stocks
4/3/23
1 élément de Couverture média
Presse/Média: Research
-
Weekly: Anatara Lifesciences (ANR: 2.80c) trading at high volume
6/12/23
1 élément de Couverture média
Presse/Média: Research
-
Findings in Fabry Disease Reported from Charles University and General University Hospital Prague (Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, ...)
11/8/23
1 élément de Couverture média
Presse/Média: Research